摘要
目的 探究尼拉帕利联合贝伐珠单抗治疗晚期卵巢癌的效果.方法 选取2020 年9 月—2023 年9 月就诊的80 例晚期卵巢癌,采用随机数字表法分为观察组和对照组各40 例,观察组在TP化疗基础上给予贝伐珠单抗联合尼拉帕利治疗,对照组在TP化疗基础上给予贝伐珠单抗治疗,均治疗4 个周期.对比2 组疗效及治疗前后血清癌抗原(CA)125、CA153、人附睾蛋白4(HE4)、缺氧诱导因子-1α(HIF-1α)、血管生成素-2(Ang-2)、血管内皮生长因子(VEGF)、B淋巴细胞瘤-2(Bcl-2)、B细胞CLL/淋巴瘤2 关联凋亡基因-1(Bag-1)、CD3+、CD4+、CD4+/CD8+,以及毒副反应发生率.结果 观察组总有效率为90.00%(36/40)高于对照组的72.50%(29/40)(P＜0.05);随着治疗时间的延长CA153、HE4、CA125、VEGF、Ang-2、HIF-1α、VEGF、Ang-2、HIF-1α水平逐渐降低(P＜0.05),随着治疗时间的延长观察组CD3+、CD4+、CD4+/CD8+先降低后趋于稳定,对照组呈持续降低趋势(P＜0.05).治疗 2 个、4 个周期后,观察组CA153、HE4、CA125、VEGF、Ang-2、HIF-1α、Bag-1、Bcl-2 均低于对照组,观察组 CD3+、CD4+、CD4+/CD8+均较对照组高(P＜0.05).2 组毒副反应发生率比较差异无统计学意义(P＞0.05).结论 尼拉帕利联合贝伐珠单抗治疗可调控晚期卵巢癌患者细胞凋亡因子及血管生成因子水平,缓解免疫损伤,抑制肿瘤标志物水平,提升治疗效果.
Abstract
Objective To explore the efficacy of Nilapalil combined with Bevacizumab in the treatment of advanced ovarian cancer.Methods A total of 80 patients with advanced ovarian cancer treated from September 2020 to September 2023 were selected and divided into observation group(n =40)and control group(n =40)by random number table method.The observation group was given Bevacizumab combined with Nilapalil on the basis of TP chemotherapy,and the control group was given Bevacizumab combined with TP chemotherapy for 4 cycles.The therapeutic effect of the two groups and serum canc-er antigen(CA)125,CA153,human epididymal protein 4(HE4),hypoxia-inducible factor-1α(HIF-1α),angiogenin-2(Ang-2),vascular endothelial growth factor(VEGF),B-cell lymphoma-2(Bcl-2),B-cell CLL/lymphoma-2-associated ath-anogene 1(BAG-1),CD3+,CD4+,and CD4+/CD8+before and after treatment as well as the incidence of toxic and side effects were compared in the two groups.Results The total effective rate was 90.00%(36/40)in the observation group and 72.50%(29/40)in the control group(P＜0.05).The levels of CA153,HE4,CA125,VEGF,Ang-2,HIF-1α,VEGF,Ang-2,and HIF-1α decreased gradually with the extension of treatment time.CD3+,CD4+,and CD4+/CD8+in the observation group first decreased and then stabilized with the extension of treatment time,while the control group showed a continuous decreasing trend(P＜0.05).After 2 and 4 cycles of treatment,CA153,HE4,CA125,VEGF,Ang-2,HIF-1α,Bag-1 and Bcl-2 in observation group were lower than those in control group,while CD3+,CD4+and CD4+/CD8+in ob-servation group were higher than those in control group(P＜0.05).There was no significant difference in the incidence of toxic and side effects between the two groups(P＞0.05).Conclusion Nilapalil combined with Bevacizumab can regulate the levels of apoptosis factors and angiogenesis factors in advanced ovarian cancer patients,alleviate immune damage,inhibit the level of tumor markers,and improve the therapeutic effect.
基金项目
安徽省中央引导地方科技发展专项项目(科财201858号YDZX20183400004622)
维普
万方数据